The MarketReader Minute
💊 Biohaven Surges on Breakthrough Trial Results, While IDEAYA and Viking See Declines Amid Insider Selling and Market Sentiment | Biotech Sector Insights
Biohaven Ltd. announced positive results from a pivotal study on troriluzole for treating Spinocerebellar Ataxia, demonstrating substantial improvements in disease progression rates. This announcement resulted in a 20% surge in Biohaven shares during premarket trading.